Protein A Resins Market Size, Share, and Trends 2024 to 2033

Protein A Resins Market Size and Manufacturers

The global protein A resins market size was valued at USD 1.50 billion in 2023 and is anticipated to reach around USD 2.60 billion by 2033, growing at a CAGR of 5.65% from 2024 to 2033. The increasing demand for protein A resins for drug development in the pharmaceutical industry is driving the growth of the protein a resins market.

Key Takeaways

• By region, North America led the protein A resins market with the largest market share of 42% in 2023.
• By region, Asia Pacific is expected to witness the fastest growth rate in the market during the forecast period.
• By application, the antibody purification segment dominated the protein A resins market in 2023 with market share of 60%.
• By product, the recombinant protein A segment had the largest share of around 58% in 20223.
• By matrix type, the agarose-based matrix segment dominated the market in 2023 with market share of 42.3%.
• By end-user, the pharmaceutical & biopharmaceutical companies segment dominated the market in 2023 with market share of 59%.

Protein A Resins Market Size in the U.S. 2024 to 2033

The U.S. protein a resins market was estimated at USD 490 million in 2023 and is predicted to be worth USD 840 million by 2033, at a CAGR of 5.80% from 2024 to 2033.

North America led the protein A resins market with the largest market share in 2023. The growth of the market is attributed to the rising adoption of protein A resins in drug development and the treatment of the various types of diseases that drive the growth of the market. The rising presence of the major biopharmaceuticals and life science research centers is contributing to the expansion of the market. The rising cases of diseases such as autoimmune diseases are driving the expansion of the demand for effective treatment and will boost the growth of the protein A resins market across the region. The rising government interventions in the development of drug discovery and the pharmaceutical industry and the R&D in the developed economies for the development of life science and healthcare are contributing to the expansion of the market.

Asia Pacific is expected to witness the fastest growth in the protein A resins market during the forecast period. The growth of the market in the region is attributed to the expansion of the healthcare infrastructure and rapidly growing population that drives the demand for efficient healthcare infrastructure which contributes to the growth of the market. The rising investments in the development of biopharmaceuticals and life science research centers are driving the demand for the protein A resins market in the region.

Protein A Resins Market Overview

The protein A resins market offers services associated with resins that are highly efficient chromatographic medium, used to purify monoclonal antibody products (mAbs) and immunoglobulin from a cell culture medium in a single process. Protein A chromatographic resin is essential to the purification process. It enables high purity levels while purifying therapeutic antibodies. Protein A resin is used in a variety of applications, including affinity chromatography, immunoprecipitation, biomanufacturing and bioprocessing. Because of its selectivity, resin is used as a common approach for capturing antibodies during purifying processes. Protein A resins have a high capacity and affinity. As a result, they are employed in the biopharmaceutical and life sciences industries to produce antibody products. Thus the rising demand for the protein A resin in the pharmaceutical industries is driving the growth of the market.

Growth Factors

• The rising expenditure on the biopharmaceutical and pharmaceutical industries, synthetic biology, and the rising studies on monoclonal antibodies are contributing to the expansion of the market.
• The rising demand for therapeutic antibodies across the world and the rising use of chromatography techniques for the detection of vitamins and additives in food are driving the growth of the market.
• The rising investments in drug discovery and the growing research and development activities in order to innovate and launch of new drugs are contributing to the growth of the protein A resins market.

Protein A Resins Market Scope

Protein A Resins Market Dynamics

Driver

Expanding pharmaceutical industry

The expansion of the overall global pharmaceutical industry along with the rising prevalence of chronic diseases and the demand for effective treatment and drug discovery that driving the demand for the protein A resins market. The rising investments in synthetic biology and innovations in drug discovery in the biopharmaceutical industries are contributing to the growth of the market. The increasing use of chromatography in the discovery and development of drugs is further driving the expansion of the protein A resins market.

Restraint

Higher cost

Protein A resins are much costlier than the other types of resins and no other resin can match the purification level of the protein A resins that makes it higher in cost. Protein A resins are often expensive due to the complex manufacturing processes involved and the high purity required. This cost can be a significant barrier, especially for small biotech companies or academic research labs with limited budgets. Thus, the higher cost limits the adoption of the protein A resin and restraining the growth of the protein A resins market. The production capacity for protein A resins may not be able to keep up with the growing demand, leading to shortages and increased prices. Manufacturers may struggle to scale up production due to technical challenges or regulatory constraints.

Opportunity

Rising chronic diseases

The increasing prevalence of chronic diseases such as cancer is driving the demand for monoclonal antibodies for treatment and diagnostics. Monoclonal antibodies are widely accepted in the treatment of various types of cancer that require a unique treatment type. The increasing use of monoclonal antibodies in the various types of therapeutics due to their specificity and flexibility and the demand for the protein A resin. Thus, the rising rate of cancer and other chronic diseases worldwide is driving the demand for protein A resins and opening lucrative opportunities for the expansion of the protein A resins market.

• In April 2024, Daiichi Sankyo’s Biologics License Application (BLA) and AstraZeneca accepted the US FDA for the datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative for the breast cancer.

Applications Insights

The antibody purification segment dominated the protein A resins market in 2023. The segment's growth is attributed to the rising demand for drug discovery and development, which is influencing the growth of the segment. Antibodies purification entails the selective enrichment or isolation of antibodies from ascites fluid, serum (polyclonal antibodies), or the cell culture supernatant of a hybridoma cell line (monoclonal antibodies).

The only method available for the purification of biomolecules according to their unique chemical structure or biological function is affinity chromatography. It is dependent upon the reversible interaction of a certain ligand with a protein. The basis for this is the high specificity and affinity of Protein A and Protein G for the Fc-region of lgC across various animals. An antibody can be eluted by decreasing pH, and its binding to the ligand is reversible.

Product Insights

The recombinant protein A segment projected the highest market share in 2023. Recombinant protein purification technologies are significant in modern biotechnology because they allow unique proteins to be used in a variety of applications such as research, diagnostics, and therapies. Scientists may now generate proteins of interest in heterologous host systems such as bacteria, yeast, or mammalian cells thanks to advances in genetic engineering technology. Recombinant protein purification is the process of isolating and purifying synthesized proteins utilizing recombinant DNA technology.

It entails extracting the target protein of interest from a complicated combination of other cellular components and contaminants, such as host cell proteins, nucleic acids, and culture medium components. Recombinant protein purification aims to provide a highly pure, bioactive, and homogeneous protein sample suitable for further characterization, structural investigations, therapeutic uses, or other downstream processes.

Matrix Insights

The agarose-based matrix segment dominated the protein A resins market in 2023. Agarose resins, often known as agarose beads, are agarose-based matrix materials used in column chromatography. There are two varieties of agarose resins, plain agarose beads, using gravity techniques, they should not be used for high-pressure separation. Cross-linked beads have greater physical and chemical stability than normal agarose beads. Cross-linked beads are high-intensity agarose beads that have been reacted with a specific reagent to form more cross-linked polysaccharide chains, increasing the strength and stability of the matrix.

On the other hand, the organic polymer-based matrix segment is observed to grow at a notable rate during the forecast period. Organic polymer-based matrices are well-established in the biopharmaceutical industry and have a proven track record of regulatory compliance. Manufacturers can leverage the extensive documentation and regulatory support available for these materials to streamline the regulatory approval process for protein purification applications.

End-User Insights

The biopharmaceutical companies segment dominated the market with significant growth in the market in 2023. The rising adoption of the protein A resins in the biopharmaceutical industry for the development of mAbs, drug discovery, vaccines, and therapeutics production process. The rising investments in biopharmaceutical and life science development drive the demand for protein A resins for drug discovery. Additionally, technological advancements in the pharmaceutical and biopharmaceutical industry are also expanding the growth of the market.

Regulatory bodies such as the FDA and EMA require biopharmaceutical companies to meet stringent quality and purity standards for their products. Protein A resins offer high specificity and purity in antibody purification processes, making them indispensable in complying with these regulations.

Recent Developments

• In March 2024, Ultomiris received an approval from the United States for the long-term C5 complement inhibitor for the diagnostics of geriatric patients having anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder.
• In March 2024, Merck, a leading player in the life science technology company expanded its M LabTM Collaboration Center in Shanghai, China, it is the organization’s biggest in the global network of 10 interconnected labs. The investment worth € 14 million was added for the new biology application lab an upstream application lab and a process development training center to its M LabTM Collaboration Center in Shanghai.
• In April 2024, BioArctic AB collaborated with Eisai and announced the organization submitted the supplemental Biologics License Application (sBLA) for its drug Leqembi to the United States Food and Drug Administration (FDA).
• In April 2024, the US FDA approved and authorized the latest antibody drug named Pemgarda marketed by the biotech Invivyd, to protect immunocompromised individuals from COVID-19.
• In April 2024, Kemp Proteins LLC, a leading company in gene-to-protein services and monoclonal antibody development announced the strategic collaboration with the Columbia Biosciences of Frederick, Maryland.
• In April 2024, Sino Biological introduced a series of in vitro bioassay services for maintaining antibody drug development projects. Sino Biological offers different reagents and a range of n vitro efficacy evaluation services for meeting the demand for testing practices and trends. 

Protein A Resins Market Companies

• GE Healthcare
• Merck Millipore
• PerkinElmer, Inc.
• GenScript Biotech Corp.
• Agilent Technologies
• Repligen Corp.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Abcam PLC.
• Novasep Holdings SAS

Segments Covered in the Report

By Application

• Antibody purification
• Immunoprecipitation

By Product

• Recombinant protein A
• Natural protein A

By Matrix Type

• Agarose-based matrix
• Glass or silica gel-based matrix
• Organic polymer-based matrix

By End-user

• Pharmaceutical & Biopharmaceutical Companies
• Clinical research laboratories
• Academic research institutes
• Contract research organization

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa